Tecentriq 1,200 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB26FNMNG
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,006
Award facts
- Contract value 100% obligated
- $13,005.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,005.98 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Tecentriq (atezolizumab) 1,200 mg/20 mL vials. The delivery order, issued on November 3, 2025, with an ultimate completion date of November 25, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award represents a routine pharmaceutical supply transaction executed under DMS Pharmaceutical Group's broader relationship with the Defense Logistics Agency's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.99 billion ceiling value and completion date of December 31, 2036. The PPV-G GEN V represents a $30.3 billion strategic acquisition designed to supply Department of Defense healthcare facilities worldwide with comprehensive pharmaceutical products, including branded and generic medications, biologics, and medical consumables. As a regional prime vendor contractor under this program, DMS Pharmaceutical Group serves as a critical supplier supporting military healthcare operations globally, with this delivery order exemplifying the company's role in fulfilling specialized pharmaceutical requirements for the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FNMNG?
SPE2DB26FNMNG was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 3, 2025.
How much is contract SPE2DB26FNMNG worth?
The government has obligated $13,006 on SPE2DB26FNMNG.
Is contract SPE2DB26FNMNG an order under another contract?
Yes. SPE2DB26FNMNG is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMNG competed?
The extent of competition for SPE2DB26FNMNG was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award